VSTMのチャート
VSTMの企業情報
symbol | VSTM |
---|---|
会社名 | Verastem Inc (ベラステム) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Major Pharmaceuticals |
業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連(Health Care) |
概要 | 事業概要 ヴェラステム(ベラステム)(Verastem Inc.)は生物製薬会社である。同社は、癌幹細胞(CSC)を標的とする小分子薬及びコンパニオン診断薬の発見及び開発に注力する。同社の先進的な製品候補は小分子薬「VS-507」である。同社の科学関係の共同設立者は「VS-507」を乳癌幹細胞を殺すための候補薬として同定した。平成23年11月3日現在、同社は「VS-507」を乳癌の潜在的な治療薬として臨床試験により評価している。 ベラステムは米国のバイオ医薬品企業。癌治療に焦点を当て、癌幹細胞を殺す薬剤の開発、独自コンパニオン診断の開発を行う。最新プログラムは焦点接着キナ―ゼやPI3K/mTORシグナル伝達経路治療剤など。VS-6063、VS-4718、VS-5584の製品候補を手掛け、前臨床・臨床試験にて中皮腫、卵巣癌、肺癌などの癌治療法としての評価を行う。 Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. |
本社所在地 | 117 Kendrick Street Suite 500 Needham MA 02494 USA |
代表者氏名 | Robert Forrester Robert Forrester |
代表者役職名 | President Chief Executive Officer |
電話番号 | +1 781-292-4200 |
設立年月日 | 40391 |
市場名 | NASDAQ National Market System |
ipoyear | 2012年 |
従業員数 | 69人 |
url | www.verastem.com |
nasdaq_url | https://www.nasdaq.com/symbol/vstm |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -79.08600 |
終値(lastsale) | 6.69 |
時価総額(marketcap) | 492332239.47 |
時価総額 | 時価総額(百万ドル) 458.47980 |
売上高 | 売上高(百万ドル) 10.00000 |
企業価値(EV) | 企業価値(EV)(百万ドル) 314.69180 |
当期純利益 | 当期純利益(百万ドル) -80.77800 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Verastem Inc revenues increased from $0K to $10M. Net loss increased 49% to $39.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative increase from $9.2M to $25.6M (expense) Research and development increase of 34% to $23.3M (expense). |
VSTMのテクニカル分析
VSTMのニュース
Verastem Oncology to Participate in Upcoming Investor Conferences 2023/05/01 11:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: JMP Securities Life Sciences Conference; podium presentation on Tuesday, May 16, 2023 at 1:00 p.m. ET RBC Capital Markets Global Healthcare Conference; fireside chat on Wednesday, May 17, 2023 at 2:05 p.m. ET A live webcast of the presentation and fi
DelveInsight Business Research, LLP: FAK Inhibitors Market Growing Rapidly, Estimates DelveInsight | Verastem, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, InxMed are Expected to Contribute to Growth 2023/04/25 15:06:00 Finanz Nachrichten
The dynamics of the FAK inhibitor market is anticipated to change as companies across the globe are thoroughly working toward developing new FAK options with convenient RoA and better safety profi…
FAK Inhibitors Market Growing Rapidly, Estimates DelveInsight | Verastem, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, InxMed are Expected to Contribute to Growth 2023/04/25 15:00:00 PR Newswire
The dynamics of the FAK inhibitor market is anticipated to change as companies across the globe are thoroughly working toward developing new FAK options with convenient RoA and better safety profile to treat a wide array of cancers. Key players, such as InxMed, Verastem, GlaxoSmithKline,…
Mizuho Securities Starts Verastem at Neutral 2023/03/29 20:04:04 Investing.com
https://www.investing.com/news/pro/mizuho-securities-starts-verastem-at-neutral-432SI-3044332
Verastem GAAP EPS of -$0.08 beats by $0.02 2023/03/14 20:38:27 Seeking Alpha
Verastem press release (VSTM): Q4 GAAP EPS of -$0.08 beats by $0.02.Cash, Cash Equivalents, and Investments of $87.9 Million as of December 31, 2022; Pro-Forma $117.9 Million…
Weird But Effective stocks: Gossamer Bio, Inc. (NASDAQ:GOSS), Verastem, Inc. (NASDAQ:VSTM 0.48%) 2023/02/08 11:12:02 Stock Equity
GOSS has seen its SMA50 which is now -17.21%. In looking the SMA 200 we see that the stock has seen a -68.46%. VSTM has seen its SMA50 which is … The post Weird But Effective stocks: Gossamer Bio, Inc. (NASDAQ:GOSS), Verastem, Inc. (NASDAQ:VSTM 0.48%) appeared first on Stocks Equity .
Current Trader’s Watch List: Intelligent Bio Solutions Inc. (NASDAQ:INBS -0.95%), Verastem, Inc. (NASDAQ:VSTM 0.68%) 2023/02/06 17:27:19 Stock Equity
INBS has seen its SMA50 which is now 58.26%. In looking the SMA 200 we see that the stock has seen a 21.54%. VSTM has seen its SMA50 which is … The post Current Trader’s Watch List: Intelligent Bio Solutions Inc. (NASDAQ:INBS -0.95%), Verastem, Inc. (NASDAQ:VSTM 0.68%) appeared first on Stocks Equity .
Mid-Day Active Movers: Lucira Health, Inc. (NASDAQ:LHDX -1.58%), Verastem, Inc. (NASDAQ:VSTM 1.36%) 2023/02/03 16:36:28 Stock Equity
LHDX has seen its SMA50 which is now 21.37%. In looking the SMA 200 we see that the stock has seen a -75.18%. VSTM has seen its SMA50 which is … The post Mid-Day Active Movers: Lucira Health, Inc. (NASDAQ:LHDX -1.58%), Verastem, Inc. (NASDAQ:VSTM 1.36%) appeared first on Stocks Equity .
Shocking stocks: Vera Therapeutics, Inc. (NASDAQ:VERA -15.72%), Verastem, Inc. (NASDAQ:VSTM 8.65%) 2023/02/03 13:11:42 Stock Equity
VERA has seen its SMA50 which is now -47.84%. In looking the SMA 200 we see that the stock has seen a -57.43%. VSTM has seen its SMA50 which is … The post Shocking stocks: Vera Therapeutics, Inc. (NASDAQ:VERA -15.72%), Verastem, Inc. (NASDAQ:VSTM 8.65%) appeared first on Stocks Equity .
Morning Stock Under Consideration: ContextLogic Inc. (NASDAQ:WISH 1.92%), Verastem, Inc. (NASDAQ:VSTM 2.48%) 2023/01/31 16:31:07 Stock Equity
WISH has seen its SMA50 which is now 7.45%. In looking the SMA 200 we see that the stock has seen a -44.97%. VSTM has seen its SMA50 which is … The post Morning Stock Under Consideration: ContextLogic Inc. (NASDAQ:WISH 1.92%), Verastem, Inc. (NASDAQ:VSTM 2.48%) appeared first on Stocks Equity .
Weird But Effective stocks: Gossamer Bio, Inc. (NASDAQ:GOSS), Verastem, Inc. (NASDAQ:VSTM 0.48%) 2023/02/08 11:12:02 Stock Equity
GOSS has seen its SMA50 which is now -17.21%. In looking the SMA 200 we see that the stock has seen a -68.46%. VSTM has seen its SMA50 which is … The post Weird But Effective stocks: Gossamer Bio, Inc. (NASDAQ:GOSS), Verastem, Inc. (NASDAQ:VSTM 0.48%) appeared first on Stocks Equity .
Current Trader’s Watch List: Intelligent Bio Solutions Inc. (NASDAQ:INBS -0.95%), Verastem, Inc. (NASDAQ:VSTM 0.68%) 2023/02/06 17:27:19 Stock Equity
INBS has seen its SMA50 which is now 58.26%. In looking the SMA 200 we see that the stock has seen a 21.54%. VSTM has seen its SMA50 which is … The post Current Trader’s Watch List: Intelligent Bio Solutions Inc. (NASDAQ:INBS -0.95%), Verastem, Inc. (NASDAQ:VSTM 0.68%) appeared first on Stocks Equity .
Mid-Day Active Movers: Lucira Health, Inc. (NASDAQ:LHDX -1.58%), Verastem, Inc. (NASDAQ:VSTM 1.36%) 2023/02/03 16:36:28 Stock Equity
LHDX has seen its SMA50 which is now 21.37%. In looking the SMA 200 we see that the stock has seen a -75.18%. VSTM has seen its SMA50 which is … The post Mid-Day Active Movers: Lucira Health, Inc. (NASDAQ:LHDX -1.58%), Verastem, Inc. (NASDAQ:VSTM 1.36%) appeared first on Stocks Equity .
Shocking stocks: Vera Therapeutics, Inc. (NASDAQ:VERA -15.72%), Verastem, Inc. (NASDAQ:VSTM 8.65%) 2023/02/03 13:11:42 Stock Equity
VERA has seen its SMA50 which is now -47.84%. In looking the SMA 200 we see that the stock has seen a -57.43%. VSTM has seen its SMA50 which is … The post Shocking stocks: Vera Therapeutics, Inc. (NASDAQ:VERA -15.72%), Verastem, Inc. (NASDAQ:VSTM 8.65%) appeared first on Stocks Equity .
Morning Stock Under Consideration: ContextLogic Inc. (NASDAQ:WISH 1.92%), Verastem, Inc. (NASDAQ:VSTM 2.48%) 2023/01/31 16:31:07 Stock Equity
WISH has seen its SMA50 which is now 7.45%. In looking the SMA 200 we see that the stock has seen a -44.97%. VSTM has seen its SMA50 which is … The post Morning Stock Under Consideration: ContextLogic Inc. (NASDAQ:WISH 1.92%), Verastem, Inc. (NASDAQ:VSTM 2.48%) appeared first on Stocks Equity .